Novo Nordisk appoints vp for regulatory affairs
Diabetes care specialist Novo Nordisk has appointed Per Falk as vice president for clinical, medical and regulatory affairs for North America. He brings 23 years of medical, research and pharmaceutical experience to the role where he will lead clinical research and medical affairs in endocrinology and biopharmaceuticals, as well as regulatory affairs and medical communications.
Dr Falk joined Novo Nordisk in 2002 as a vice president to establish the experimental medicine unit in Denmark. Later he worked in Tokyo where he was responsible for drug development and market authorisation of Novo Nordisk's medical entities in Japan and Australia.
In 2008, Dr Falk moved to the US as associate vice president of clinical development and medical affairs - diabetes and metabolism where he was responsible for clinical development and medical affairs for all of Novo Nordisk's diabetes and metabolism products.
